Gilead Sciences Inc. is paying Korean firm LG Life Sciences Ltd. $20 million up front for rights to a caspase inhibitor program for fibrotic diseases, which includes a Phase II-stage compound being tested in patients with hepatitis C virus. (BioWorld Today)
Gilead Sciences Inc. is paying Korean firm LG Life Sciences Ltd. $20 million up front for rights to a caspase inhibitor program for fibrotic diseases, which includes a Phase II-stage compound being tested in patients with hepatitis C virus. (BioWorld Today)
After progression-free survival data for satraplatin failed to wow an FDA advisory committee in July, GPC Biotech AG, along with partners Pharmion Corp. and Spectrum Pharmaceuticals Inc., hoped the drug's overall survival data would be impressive enough to clear the way for approval in second-line hormone-refractory prostate cancer. (BioWorld Today)
After progression-free survival data for satraplatin failed to wow an FDA advisory committee in July, GPC Biotech AG, along with partners Pharmion Corp. and Spectrum Pharmaceuticals Inc., hoped the drug's overall survival data would be impressive enough to clear the way for approval in second-line hormone-refractory prostate cancer. (BioWorld Today)
If the story of newly established Relypsa Inc., a company created to develop nonabsorbed polymeric drugs for renal and cardiovascular diseases, sounds more than a little familiar, that's probably because it is. (BioWorld Today)
